Klacid I.V. (Clarithromycin)

Klacid I.V. (clarithromycin) is employed to treat bacterial infections that are susceptible to macrolide therapy.

• Community‑acquired pneumonia: achieves clinical cure and bacterial eradication.
• Acute bacterial sinusitis: reduces symptoms and clears infection.
• Skin and soft‑tissue infections: resolves cellulitis, abscesses and related conditions.
• Mycobacterial infections (e.g., Mycobacterium avium complex): used in combination regimens to suppress disease progression.
• Helicobacter pylori eradication (in combination therapy): contributes to successful eradication when paired with other agents.

• Clarithromycin binds to the 50S subunit of bacterial ribosomes, inhibiting the translocation step of protein synthesis. This action blocks the elongation of the peptide chain, resulting in a bacteriostatic effect against susceptible organisms. By preventing the production of essential proteins, the drug curtails bacterial growth and facilitates clearance by the immune system.

Clarithromycin administered intravenously may be associated with a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools.
• Abdominal pain: cramping or discomfort.
• Taste disturbance: altered taste perception.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or jaundice.
• QT prolongation: cardiac rhythm changes that may lead to arrhythmia.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile infection: risk of severe colitis.

When prescribing Klacid I.V., clinicians should consider several safety factors.

• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Hepatic disease: monitor liver function tests during therapy.
• Cardiac risk: avoid in patients with known QT prolongation or who are taking other QT‑prolonging drugs.
• Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
• Drug interactions: review concomitant medications for potential macrolide interactions.
• Store at below 25°C: keep in original container, protect from light and moisture.

Clarithromycin can affect the plasma levels of several co‑administered drugs.

Major Interactions (Avoid)

• Concomitant use with cisapride or pimozide: may cause serious cardiac arrhythmias.
• Co‑administration with ergot alkaloids: risk of ergotism due to increased plasma levels.
• Simultaneous use with colchicine in renal impairment: heightened risk of toxicity.

Moderate Interactions (Monitor Closely)

• Statins (e.g., simvastatin, lovastatin): increased risk of myopathy; consider dose reduction.
• Warfarin: may enhance anticoagulant effect; monitor INR closely.
• Carbamazepine or phenytoin: may reduce clarithromycin levels; monitor therapeutic response.